This is Hypericum perforatum — St John's Wort. One of the most thoroughly studied medicinal plants in the world. And it has a drug interaction that can cause real harm. I'm going to tell you about that drug interaction honestly — because if I don't, you should not trust anything else I say.
The concern — stated in full.
St John's Wort activates a receptor in your liver called the pregnane X receptor. This causes your liver to produce more of an enzyme called CYP3A4, and more of a transporter protein called P-glycoprotein. Those two things work together to clear drugs out of your bloodstream faster. If someone is taking a drug that depends on a certain blood concentration to work — a transplant anti-rejection drug, an antiretroviral for HIV, an oral contraceptive, a blood thinner — St John's Wort can reduce their blood levels to the point where the drug no longer works.
This is not theoretical. There are documented cases of organ rejection in transplant patients who started taking St John's Wort alongside ciclosporin. There are documented cases of HIV treatment failure. There are documented cases of contraceptive failure. These are serious outcomes. Responsible practitioners, and I include myself in that, take this interaction extremely seriously.
The EU, the MHRA, and multiple regulatory bodies have issued warnings about these interactions. Those warnings are scientifically justified.
So why am I arguing that restricting St John's Wort is a disproportionate response? Because the interaction mechanism is fully characterised, clinically manageable, and — critically — does not apply to all preparations of St John's Wort.
The hyperforin distinction.
The mechanism has been precisely identified. The constituent responsible for CYP3A4 and P-glycoprotein induction is hyperforin — a phloroglucinol derivative present in standard St John's Wort extracts at approximately 3 to 6 percent by weight. It is not hypericin. This is a common regulatory misunderstanding — hypericin has antiviral and other properties, but it is not the interaction driver.
And here is what changes the entire regulatory picture: low-hyperforin preparations of St John's Wort — preparations standardised to less than 1% hyperforin, such as the Ze 117 extract commercially known as Remotiv — have been tested in clinical pharmacokinetic studies. The studies are published. The result is clear: no significant CYP3A4 or P-glycoprotein induction. The drug interactions that have caused harm with standard high-hyperforin extracts do not occur with authenticated low-hyperforin preparations.
This has been replicated. A 2019 study published in PMC confirms: low-dose hyperforin extracts exert no significant effects on CYP3A4 or P-glycoprotein. The interaction risk is reformulation-manageable. It is a property of a specific constituent at a specific concentration — not a property of the herb itself.
The efficacy evidence.
The Cochrane systematic review by Linde and colleagues — 29 randomised clinical trials — found St John's Wort superior to placebo for mild to moderate depression and similarly effective to standard antidepressants. Patients on St John's Wort dropped out due to adverse effects approximately four times less often than patients on older antidepressant drugs. The comparison was against tricyclics, not SSRIs — be precise about that. But the clinical burden of adverse effects from St John's Wort is substantially lower than from pharmaceutical alternatives.
There is no hepatotoxicity signal with St John's Wort. None. This herb, which carries a real and manageable drug interaction risk, has zero liver injury cases in the clinical literature.
Compare that to SSRIs and SNRIs, which carry documented withdrawal syndromes, sexual dysfunction, weight changes, and QT prolongation with some agents. These remain available over the counter in some jurisdictions and by prescription without restriction elsewhere. The interaction profile of St John's Wort, which is entirely manageable through prescriber screening, is being treated as a blanket prohibition justification.
What proportionate regulation looks like.
Prescriber awareness. Contraindication screening for CYP3A4-sensitive drugs — immunosuppressants, antiretrovirals, certain chemotherapy, anticoagulants, oral contraceptives. Use of authenticated low-hyperforin preparations where interactions are a clinical concern. This achieves everything legitimate safety management requires without prohibition.
And again, the information vacuum: St John's Wort products cannot legally tell you about these interactions on the label under food supplement law. The information that would prevent harm is prohibited. That is the reform needed — not a ban.
The constitutional close.
Mental health is a public health crisis. St John's Wort is an evidence-based option for mild to moderate depression that carries fewer adverse effects than pharmaceutical alternatives. The drug interaction risk is real, characterised, and manageable. A proportionate regulatory response is prescriber guidance and standardisation of hyperforin content — not removal from the shelves.
The UK has committed to align food supplement law with EU restrictions under the SPS Agreement — without parliamentary approval. That commitment is published at www.gov.uk/government/news/uk-eu-sps-agreement-legislation-in-scope .
Sign the petition. Respond to the EU consultation. Write to your MP at writetothem.com. Ask them: did you vote for this? Should you have?https://www.change.org/p/demand-uk-regain-control-over-food-supplements-regulation?recruiter=1403120945&recruited_by_id=ca366360-0a66-11f1-a119-071922cd5010&utm_source=share_petition&utm_campaign=petition_dashboard&utm_medium=copylink&share_id=Qv72WrhZDN
#RightToHeal #HerbalAccessNI #SaveOurSupplements
